Status:
UNKNOWN
Intracoronary of Nicorandil and Verapamil to Reduce the Occurrence of Periprocedural Myocardial Injury
Lead Sponsor:
The First Affiliated Hospital of Zhejiang Chinese Medical University
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
Percutaneous coronary intervention (PCI) remains the major revascularization strategy for patients with obstructive coronary artery disease (CAD).However,in a substantial number of PCI cases for acute...
Detailed Description
Simple randomization in a 1:1 ratio will be made in blocks of variable size according to a random numbers generated by Excel 2019 to divide the patients to treatment group (Nicorandil and verapamil) a...
Eligibility Criteria
Inclusion
- diagnosis of CHD with FFR\<0.8;2.elective PCI;
Exclusion
- Patients with AMI, lesion at the opening of the main coronary artery，kidney dysfunction, Liver dysfunction，blood coagulation disorder ,NYHA III-IV,Degree II-III atrioventricular block,and restenosis after PCI，CABG will be excluded.
Key Trial Info
Start Date :
May 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 17 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05399576
Start Date
May 17 2022
End Date
September 17 2023
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
yuangang Qiu
Hangzhou, Zhejiang, China, 310006